Search

Your search keyword '"Laurence A"' showing total 1,617 results
Start Over Author "Laurence A" Journal journal of urology
1,617 results on '"Laurence A"'

3. MP62-11 BENIGN PROSTATIC HYPERPLASIA SURGICAL RETREATMENT: A RETROSPECTIVE COHORT ANALYSIS OF A NATIONWIDE DATABASE

Author

Manfredi, Celeste, primary, Licari, Leslie, additional, Ditonno, Francesco, additional, Franco, Antonio, additional, Bologna, Eugenio, additional, Sturgis, Morgan, additional, De Sio, Marco, additional, Setia, Shaan, additional, Olweny, Ephrem, additional, Coogan, Christopher, additional, Levine, Laurence, additional, Cherullo, Edward, additional, and Autorino, Riccardo, additional

Published
2024
Full Text
View/download PDF

5. PD18-11 DELAYED PARTIAL NEPHRECTOMY FOLLOWING COMPLETE RESPONSE TO IMMUNOTHERAPY: FEASIBILITY AND RESULTS (UROCCR N°157)

Author

Margue, Gaëlle, primary, Parier, Bastien, additional, Albiges, Laurence, additional, Klein, Clément, additional, Pignot, Géraldine, additional, Gravis, Gwenaëlle, additional, Bigot, Pierre, additional, Baize, Nathalie, additional, Ingels, Alexandre, additional, Joly, Charlotte, additional, Audenet, François, additional, Vano, Yann, additional, Waeckel, Thibaut, additional, Levard, Romain, additional, Gross-Goupil, Marine, additional, and Bernhard, Jean-Christophe, additional

Published
2024
Full Text
View/download PDF

6. MP02-18 APPROPRIATENESS OF IMAGING FOR LOW-RISK PROSTATE CANCER – REAL WORLD DATA FROM THE PENNSYLVANIA UROLOGIC REGIONAL COLLABORATION (PURC)

Author

Mercedes, Raidizon, primary, Zook, Elizabeth, additional, Eidelman, Eric, additional, Tomaszewski, Jeffrey, additional, Ginzburg, Serge, additional, Uzzo, Robert, additional, Smaldone, Marc, additional, Danella, John, additional, Guzzo, Thomas J., additional, Lee, Daniel, additional, Belkoff, Laurence, additional, Walker, Jeffrey, additional, Reese, Adam, additional, Shah, Mihir, additional, Jacobs, Bruce, additional, and Raman, Jay D., additional

Published
2024
Full Text
View/download PDF

8. MP41-08 UTILIZING PATIENT-REPORTED OUTCOMES TO ASSESS THE IMPACT OF UNIVERSAL GERMLINE GENETIC TESTING FOR PROSTATE CANCER

Author

Shore, Neal, primary, Pieczonka, Christopher M., additional, Heron, Sean, additional, Gazi, Mukaram, additional, Cahn, David J., additional, Belkoff, Laurence, additional, Berger, Aaron D., additional, Mazzarella, Brian, additional, Morris, David, additional, Veys, Joseph, additional, Bevan-Thomas, Richard, additional, Engelman, Alexander, additional, Dato, Paul, additional, Cornell, Robert, additional, Wise, David R., additional, Hardwick, Mary Kay, additional, Hatchell, Kathryn E., additional, Heald, Brandie, additional, Nussbaum, Robert L., additional, Nielsen, Sarah M., additional, and Esplin, Edward D., additional

Published
2024
Full Text
View/download PDF

9. MP68-07 PROPORTION OF GLEASON 8-10 PROSTATE CANCER FOUND ON BIOPSY AND TUMOR AGGRESSIVENESS IN MATCHED COHORTS OF MEN IN ASIA AND WESTERN COUNTRIES

Author

Dong, Liang, primary, Lajkosz, Katherine, additional, Sanchez-Salas, Rafael, additional, Tiwari, Raj Vikesh, additional, Dias dos Santos, Caio Pasquali, additional, Dong, Baijun, additional, Pan, Jiahua, additional, Chan, Amy, additional, Woon, Dixon, additional, Kulkarni, Girish S., additional, Perlis, Nathan, additional, Hamilton, Rob, additional, Klotz, Laurence, additional, Wallis, Christopher J. D., additional, Macek, Petr, additional, Kae, Jack Tay, additional, Toi, Ants, additional, Finelli, Antonio, additional, Fleshner, Neil E., additional, Cathelineau, Xavier, additional, van der Kwast, Theodorus H., additional, Xue, Wei, additional, and Zlotta, Alexandre R., additional

Published
2024
Full Text
View/download PDF

11. MP09-02 BENIGN PROSTATIC HYPERPLASIA SURGERY: A CONTEMPORARY TEN-YEAR ANALYSIS OF USAGE TRENDS AND COSTS FROM A LARGE US DATABASE

Author

Manfredi, Celeste, primary, Ditonno, Francesco, additional, Franco, Antonio, additional, Bologna, Eugenio, additional, Licari, Leslie, additional, Sturgis, Morgan, additional, De Sio, Marco, additional, Setia, Shaan, additional, Coogan, Christopher, additional, Olweny, Ephrem, additional, Levine, Laurence, additional, Cherullo, Edward, additional, and Autorino, Riccardo, additional

Published
2024
Full Text
View/download PDF

12. Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.

Author

Shore, Neal, Pieczonka, Christopher, Heron, Sean, Gazi, Mukaram, Cahn, David, Belkoff, Laurence H., Berger, Aaron, Mazzarella, Brian, Veys, Joseph, Idom, Charles, Morris, David, Jayram, Gautam, Engelman, Alexander, Dato, Paul, Bevan-Thomas, Richard, Wise, David R., Hardwick, Mary Kay, Rojahn, Susan, Layman, Paige, and Heald, Brandie

Published
2024
Full Text
View/download PDF

13. Assessing 'Spin' in Urology Randomized Controlled Trials With Statistically Nonsignificant Primary Outcomes

Author

Jeremy Wu, Wilson Ho, Laurence Klotz, Morgan Yuan, Jason Y. Lee, and Yonah Krakowsky

Subjects
Urology
Abstract

"Spin" refers to a form of language manipulation that positively reflects negative findings or downplays potential harms. Spin has been reported in randomized controlled trials of other surgical specialties, which can lead to the recommendation of subpar or ineffective treatments. The goal of this study was to characterize spin strategies and severity in statistically nonsignificant urology randomized controlled trials.A comprehensive search of MEDLINE and Embase for the top 5 urology journals, major urology subspecialty journals, and high-impact nonurology journals from 2019 to 2021 was conducted. Statistically nonsignificant randomized controlled trials with a defined primary outcome were included. Screening, data extraction, and spin assessment were performed in duplicate by 2 independent reviewers.From the database search of 4,339 studies, 46 trials were included for analysis. Spin was identified in 35 studies (76%), with the majority of abstracts (n = 26, 57%) and main texts (n = 35, 76%) containing some level of spin. "Obscuring the statistical nonsignificance of the primary outcome and focusing on statistically significant secondary results" was the most frequently used strategy in abstracts, while "other" strategies not previously defined were the most commonly used strategies in main texts. Moderate or high spin severity was identified in 21 (46%) abstract and 22 (48%) main text conclusions.Overall, our results suggest that 76% of statistically nonsignificant urology randomized controlled trials contained some level of spin. Readers and writers should be aware of common spin strategies when interpreting nonsignificant results and critically appraise the significance of results when making decisions for clinical practice.

Published
2023

14. Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment

Author

Craig V, Labbate, Laurence, Klotz, Monica, Morrow, Matthew, Cooperberg, Laura, Esserman, and Scott E, Eggener

Subjects
Male, Urology, Humans, Prostatic Neoplasms, Breast Neoplasms, Randomized Controlled Trials as Topic
Abstract

Our goal was to review the history of the adoption of focal therapy for breast and prostate cancer and review common barriers to implementation.A narrative review of the literature was performed of English-language MEDLINE indexed articles of breast-conservation therapy and prostate cancer focal therapy.The introduction of focal therapy in breast cancer began with pioneering case series, and multiple randomized trials were performed prior to widespread adoption. Focal therapy for prostate cancer has just started the process of clinical trials with a single published randomized controlled trial. Commonly cited barriers to the adoption of prostate focal therapy include historical views of Halstedian tumor biology, tumor multifocality, over-detection, limitations in prostate imaging, and trial design end points.The adoption of breast-conserving therapy evolved over decades and used data from multiple large, randomized, clinical trials. Barriers to the adoption of prostate cancer local therapy are similar to those faced by breast cancer clinical trials. Completion of well-designed trials in prostate cancer focal therapy is essential for its evidence-based adoption.

Published
2023

15. Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer

Author

Christopher J. Magnani, Tina Hernandez-Boussard, Laurence C. Baker, Jeremy D. Goldhaber-Fiebert, and James D. Brooks

Subjects
Image-Guided Biopsy, Male, Cost-Benefit Analysis, Urology, Humans, Prostatic Neoplasms, Prospective Studies, Multiparametric Magnetic Resonance Imaging, Watchful Waiting, Magnetic Resonance Imaging, Article
Abstract

PURPOSE: Many localized prostate cancers will follow an indolent course. Management has shifted toward active surveillance (AS), yet an optimal regimen remains controversial especially regarding expensive multiparametric magnetic resonance imaging (MRI). We aimed to assess cost-effectiveness of MRI in AS protocols. MATERIALS AND METHODS: A probabilistic microsimulation modeled individual patient trajectories for men diagnosed with low-risk cancer. We assessed no surveillance, up-front treatment (surgery or radiation), and scheduled AS protocols incorporating transrectal ultrasound-guided (TRUS) biopsy or MRI based regimens at serial intervals. Lifetime quality-adjusted life-years and costs adjusted to 2020 US$ were used to calculate expected net monetary benefit at $50,000/quality-adjusted life-year and incremental cost-effectiveness ratios. Uncertainty was assessed with probabilistic sensitivity analysis and linear regression metamodeling. RESULTS: Conservative management with AS outperformed up-front definitive treatment in a modeled cohort reflecting characteristics from a multi-institutional trial. Biopsy decision conditional on positive imaging (MRI triage) at 2-year intervals provided the highest expected net monetary benefit (incremental cost-effectiveness ratio $44,576). Biopsy after both positive and negative imaging (MRI pathway) and TRUS biopsy based regimens were not cost-effective. MRI triage resulted in fewer biopsies while reducing metastatic disease or cancer death. Results were sensitive to test performance and cost. MRI triage was the most likely cost-effective strategy on probabilistic sensitivity analysis. CONCLUSIONS: For men with low-risk prostate cancer, our modeling demonstrated that AS with sequential MRI triage is more cost-effective than biopsy regardless of imaging, TRUS biopsy alone or immediate treatment. AS guidelines should specify the role of imaging, and prospective studies should be encouraged.

Published
2022

17. PD21-11 REAL WORLD IMPACT OF GERMLINE GENETIC TESTING ON CLINICAL DECISION MAKING FOR PROSTATE CANCER PATIENTS

Author

Shore, Neal, primary, Pieczonka, Christopher, additional, Gazi, Mukaram, additional, Heron, Sean, additional, Modh, Rishi, additional, Cahn, David, additional, Belkoff, Laurence H, additional, Berger, Aaron, additional, Mazzarella, Brian, additional, Morris, David, additional, Veys, Joseph, additional, Engelman, Alexander, additional, Dato, Paul, additional, Bevan-Thomas, Richard, additional, Cornell, Robert, additional, Wise, David, additional, Idom, Charles, additional, Hardwick, Mary Kay, additional, Layman, Paige, additional, Hatchell, Kathryn, additional, Heald, Brandie, additional, Young, Sarah, additional, Nussbaum, Robert L, additional, and Esplin, Edward D., additional

Published
2023
Full Text
View/download PDF

18. LBA02-03 FIRST RESULTS FROM SunRISE-1 IN PATIENTS WITH BCG UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER RECEIVING TAR-200 IN COMBINATION WITH CETRELIMAB, TAR-200, OR CETRELIMAB ALONE

Author

Daneshmand, Siamak, primary, van der Heijden, Michiel S, additional, Jacob, Joseph M, additional, Necchi, Andrea, additional, Xylinas, Evanguelos, additional, Morris, David S, additional, Spiegelhalder, Philip, additional, Zainfeld, Daniel, additional, Kang, Taek Won, additional, Matulay, Justin T, additional, Belkoff, Laurence H, additional, Decaestecker, Karel, additional, Arentsen, Harm, additional, Hampras, Shalaka, additional, Jin, Shu, additional, Cutie, Christopher J, additional, Sweiti, Hussein, additional, Stromberg, Katherine, additional, Martin, Jason, additional, and Simone, Giuseppe, additional

Published
2023
Full Text
View/download PDF

20. MP29-01 RAPID, DURABLE, AND DEEP PROSTATE-SPECIFIC ANTIGEN RESPONSE FOLLOWING ADDITION OF DAROLUTAMIDE TO ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN ARASENS

Author

Saad, Fred, primary, Tombal, Bertrand, additional, Hussain, Maha, additional, Fizazi, Karim, additional, Sternberg, Cora N., additional, Crawford, E. David, additional, Nordquist, Luke T., additional, Tutrone, Ronald, additional, Shore, Neal D., additional, Belkoff, Laurence, additional, Kapur, Shivani, additional, Jhaveri, Jay, additional, Ortiz, Jorge, additional, Srinivasan, Shankar, additional, Verholen, Frank, additional, and Smith, Matthew R., additional

Published
2023
Full Text
View/download PDF

21. MP63-01 AN INTERIM ANALYSIS OF A PHASE II CLINICAL STUDY OF INTRAVESICAL PHOTO DYNAMIC THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS)

Author

Kulkarni, Girish, primary, Richards, Kyle, additional, Black, Peter C., additional, Rendon, Ricardo, additional, Chin, Joseph, additional, Shore, Neal, additional, Jayram, Gautam, additional, Kramolowsky, Eugene, additional, Saltzstein, Daniel, additional, Agarwal, Piyush, additional, Belkoff, Laurence, additional, O'Donnell, Michael, additional, Kamat, Ashish M., additional, Zlotta, Alexandre, additional, Jewett, Michael A. S., additional, Lamm, Donald, additional, DeGruttola, Victor, additional, Mandel, Arkady, additional, Dumoulin-White, Roger J., additional, and Kassouf, Wassim, additional

Published
2023
Full Text
View/download PDF

22. MP29-02 EFFICACY AND SAFETY OF DAROLUTAMIDE IN COMBINATION WITH ANDROGEN-DEPRIVATION THERAPY AND DOCETAXEL IN THE NORTH AMERICAN POPULATION FROM ARASENS

Author

Shore, Neal D., primary, Tombal, Bertrand, additional, Hussain, Maha, additional, Saad, Fred, additional, Fizazi, Karim, additional, Sternberg, Cora N., additional, Crawford, E. David, additional, Nordquist, Luke, additional, Tutrone, Ronald, additional, Belkoff, Laurence, additional, Kapur, Shivani, additional, Jhaveri, Jay, additional, Srinivasan, Shankar, additional, Joensuu, Heikki, additional, and Smith, Matthew R., additional

Published
2023
Full Text
View/download PDF

23. LBA03-08 PEMBROLIZUMAB (PEMBRO) FOR PATIENTS (PTS) WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG): EFFICACY AND EVALUATION OF SUBSEQUENT CYSTECTOMY FROM COHORT B OF THE PHASE 2 KEYNOTE-057 STUDY

Author

Singer, Eric, primary, Necchi, Andrea, additional, Roumiguié, Mathieu, additional, Esen, Ahmet Adil, additional, Lebret, Thierry, additional, de Wit, Ronald, additional, Bajorin, Dean F., additional, Krieger, Laurence E. M., additional, Kandori, Shuya, additional, Uchio, Edward M., additional, Seo, Ho Kyung, additional, Boormans, Joost, additional, Kamat, Ashish M., additional, Grivas, Petros, additional, Nishiyama, Hiroyuki, additional, Baranwal, Pranshu, additional, Kapadia, Ekta, additional, Van den Sigtenhorst-Fijlstra, Margot, additional, Kulkarni, Girish S., additional, and Shore, Neal D., additional

Published
2023
Full Text
View/download PDF

29. MP63-05 OUTCOMES IN PATIENTS (PTS) WITH BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE HIGH-RISK (HR) NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) WHO UNDERWENT RADICAL CYSTECTOMY (RC) FOLLOWING PEMBROLIZUMAB (PEMBRO) TREATMENT IN KEYNOTE-057 COHORT A

Author

Kulkarni, Girish S., primary, Kamat, Ashish M., additional, Uchio, Edward M., additional, Roumiguié, Mathieu, additional, Krieger, Laurence E. M., additional, Singer, Eric A., additional, Bajorin, Dean F., additional, Grivas, Petros, additional, Seo, Ho Kyung, additional, Nishiyama, Hiroyuki, additional, Konety, Badrinath R., additional, Wit, Ronald de, additional, Kapadia, Ekta, additional, Xing, Aiwen, additional, Fijlstra, Margot Van den Sigtenhorst, additional, and Boormans, Joost L., additional

Published
2023
Full Text
View/download PDF

30. MP73-05 PIVOTAL STUDY OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) OF LOCALIZED PROSTATE CANCER: 4-YEAR FOLLOW UP

Author

Pavlovich, Christian, primary, Eggener, Scott, additional, Koch, Michael, additional, Penson, David, additional, Relle, James, additional, Raman, Steven, additional, Lotan, Yair, additional, Futterer, Jurgen, additional, Hatiboglu, Gencay, additional, Serrallach, Marc, additional, Heidenreich, Axel, additional, Oto, Aytekin, additional, Haider, Masoom, additional, Sedelaar, J.P. Michiel, additional, Tirkes, Temel, additional, Arora, Sandeep, additional, Macura, Katarzyna, additional, Costa, Daniel, additional, Pantuck, Allan, additional, Bomers, Joyce, additional, Bonekamp, David, additional, Persigehl, Thorsten, additional, Clarke, Gina, additional, Staruch, Robert, additional, Chin, Joseph, additional, and Klotz, Laurence, additional

Published
2023
Full Text
View/download PDF

32. Diagnostic Performance and Safety of 18 F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)

Author

Ashesh B. Jani, Gregory C. Ravizzini, Benjamin A. Gartrell, Barry A. Siegel, Przemyslaw Twardowski, Daniel Saltzstein, Mark T. Fleming, Albert Chau, Phillip Davis, Brian F. Chapin, David M. Schuster, Mohamad Allaf, Ryan J. Avery, Norbert Avril, Helen Barker, Laurence Belkoff, Peter Bostrom, Michael L. Cher, Diane Chisholm, Matthew F. Covington, Ian Cox, Giuseppe Esposito, Peter Gardiner, David Gauden, Brian Helfand, Rick Hermsen, David Josephson, Matthew Kay, Bridget F. Koontz, Lale Kostakoglu, Phillip Kuo, William Lavely, Ing Han Liem, Mary Lokuta, Benjamin Lowentritt, Jeff Michalski, Matthew P. Miller, Karen Mourtzikos, Russell Pachynski, Ross Penny, Morand Piert, Andrei Purysko, Soroush Rais-Bahrami, Bital Savir-Baruch, Rik Somford, Ashutosh Tewari, Edward Uchio, Don Yoo, and Katherine Zukotynski

Subjects
Urology
Published
2023

33. LBA03-08 PEMBROLIZUMAB (PEMBRO) FOR PATIENTS (PTS) WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG): EFFICACY AND EVALUATION OF SUBSEQUENT CYSTECTOMY FROM COHORT B OF THE PHASE 2 KEYNOTE-057 STUDY

Author

Eric Singer, Andrea Necchi, Mathieu Roumiguié, Ahmet Adil Esen, Thierry Lebret, Ronald de Wit, Dean F. Bajorin, Laurence E. M. Krieger, Shuya Kandori, Edward M. Uchio, Ho Kyung Seo, Joost Boormans, Ashish M. Kamat, Petros Grivas, Hiroyuki Nishiyama, Pranshu Baranwal, Ekta Kapadia, Margot Van den Sigtenhorst-Fijlstra, Girish S. Kulkarni, and Neal D. Shore

Subjects
Urology
Published
2023

39. MP63-01 AN INTERIM ANALYSIS OF A PHASE II CLINICAL STUDY OF INTRAVESICAL PHOTO DYNAMIC THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS)

Author

Girish Kulkarni, Kyle Richards, Peter C. Black, Ricardo Rendon, Joseph Chin, Neal Shore, Gautam Jayram, Eugene Kramolowsky, Daniel Saltzstein, Piyush Agarwal, Laurence Belkoff, Michael O'Donnell, Ashish M. Kamat, Alexandre Zlotta, Michael A. S. Jewett, Donald Lamm, Victor DeGruttola, Arkady Mandel, Roger J. Dumoulin-White, and Wassim Kassouf

Subjects
Urology
Published
2023

40. PD21-11 REAL WORLD IMPACT OF GERMLINE GENETIC TESTING ON CLINICAL DECISION MAKING FOR PROSTATE CANCER PATIENTS

Author

Neal Shore, Christopher Pieczonka, Mukaram Gazi, Sean Heron, Rishi Modh, David Cahn, Laurence H Belkoff, Aaron Berger, Brian Mazzarella, David Morris, Joseph Veys, Alexander Engelman, Paul Dato, Richard Bevan-Thomas, Robert Cornell, David Wise, Charles Idom, Mary Kay Hardwick, Paige Layman, Kathryn Hatchell, Brandie Heald, Sarah Young, Robert L Nussbaum, and Edward D. Esplin

Subjects
Urology
Published
2023

41. LBA02-03 FIRST RESULTS FROM SunRISE-1 IN PATIENTS WITH BCG UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER RECEIVING TAR-200 IN COMBINATION WITH CETRELIMAB, TAR-200, OR CETRELIMAB ALONE

Author

Siamak Daneshmand, Michiel S van der Heijden, Joseph M Jacob, Andrea Necchi, Evanguelos Xylinas, David S Morris, Philip Spiegelhalder, Daniel Zainfeld, Taek Won Kang, Justin T Matulay, Laurence H Belkoff, Karel Decaestecker, Harm Arentsen, Shalaka Hampras, Shu Jin, Christopher J Cutie, Hussein Sweiti, Katherine Stromberg, Jason Martin, and Giuseppe Simone

Subjects
Urology
Published
2023

42. MP63-05 OUTCOMES IN PATIENTS (PTS) WITH BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE HIGH-RISK (HR) NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) WHO UNDERWENT RADICAL CYSTECTOMY (RC) FOLLOWING PEMBROLIZUMAB (PEMBRO) TREATMENT IN KEYNOTE-057 COHORT A

Author

Girish S. Kulkarni, Ashish M. Kamat, Edward M. Uchio, Mathieu Roumiguié, Laurence E. M. Krieger, Eric A. Singer, Dean F. Bajorin, Petros Grivas, Ho Kyung Seo, Hiroyuki Nishiyama, Badrinath R. Konety, Ronald de Wit, Ekta Kapadia, Aiwen Xing, Margot Van den Sigtenhorst Fijlstra, and Joost L. Boormans

Subjects
Urology
Published
2023

44. MP73-05 PIVOTAL STUDY OF MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) OF LOCALIZED PROSTATE CANCER: 4-YEAR FOLLOW UP

Author

Christian Pavlovich, Scott Eggener, Michael Koch, David Penson, James Relle, Steven Raman, Yair Lotan, Jurgen Futterer, Gencay Hatiboglu, Marc Serrallach, Axel Heidenreich, Aytekin Oto, Masoom Haider, J.P. Michiel Sedelaar, Temel Tirkes, Sandeep Arora, Katarzyna Macura, Daniel Costa, Allan Pantuck, Joyce Bomers, David Bonekamp, Thorsten Persigehl, Gina Clarke, Robert Staruch, Joseph Chin, and Laurence Klotz

Subjects
Urology
Published
2023

46. Low Serum Testosterone in Men with Newly Diagnosed Androgen-Deprivation Therapy-Naïve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors: A RADICAL-PC Substudy

Author

Jehonathan H. Pinthus, Wilhelmina C. M. Duivenvoorden, Laurence Klotz, Som D. Mukherjee, D. Robert Siemens, Tamim Niazi, Vincent Fradet, William Foster, Emmanuelle Duceppe, Daniel Taussky, Robert Hamilton, Luke Lavallée, Ian Brown, Joseph Chin, Darin Gopaul, Anthony Wassef, Wassim Kassouf, Margot Davis, Philippe D. Violette, Steve Agapay, Kumar Balasubramanian, Rajibul Mian, Sumathy Rangarajan, Alp Sener, Bobby Shayegan, P. J. Devereaux, and Darryl P. Leong

Subjects
Aged, 80 and over, Male, Urology, Prostatic Neoplasms, Androgen Antagonists, Middle Aged, Cohort Studies, Cross-Sectional Studies, Cardiovascular Diseases, Androgens, Humans, Testosterone, Prospective Studies, Aged
Abstract

Cardiovascular disease is a common cause of death in prostate cancer patients. Low testosterone is associated with increased cardiovascular risk in the general male population. We investigated the relationship between serum testosterone, cardiovascular disease and risk factors in androgen-deprivation therapy-naïve prostate cancer patients.We performed a cross-sectional analysis of a subgroup of 1,326 androgen-deprivation therapy-naïve men from RADICAL-PC (Role of Androgen-Deprivation Therapy In CArdiovascular Disease-A Longitudinal Prostate Cancer study) in whom serum testosterone was measured at baseline. RADICAL-PC is a prospective multicenter cohort study of men (2,565) enrolled within 1 year of prostate cancer diagnosis, or within 6 months of commencing androgen-deprivation therapy for the first time. Cardiovascular risk factors, cancer characteristics and total serum testosterone were collected at baseline. Low testosterone was defined as total serum testosterone11 nmol/L (320 ng/dL). A Framingham cardiovascular risk score ≥15 was considered high risk for future cardiovascular events. We performed logistic regression to calculate odds ratios for the association between testosterone and cardiovascular risk.Among 1,326 participants (median age 67 years, range 45-93), 553 (42%) had low testosterone. Low testosterone was associated with existing cardiovascular disease, diabetes, elevated hemoglobin A1c, obesity, hypertriglyceridemia, low high-density lipoprotein cholesterol, hypertension and Framingham score15. Among patients with low testosterone, the odds ratio for high cardiovascular risk was 1.33 (1.02-1.73) after adjusting for ethnicity, education, alcohol use, cancer characteristics, physical activity and body mass index.Among androgen-deprivation therapy-naïve prostate cancer patients, low testosterone is common and associated with increased cardiovascular risk factors.

Published
2022

49. Socio-Environmental Conditions Associated with Geospatial Clusters of Urothelial Carcinoma: A Multi-Institutional Analysis

Author

Guy Bernstein, Sharon Larson, Daniel Kim, Zachariah Taylor, Laurence Belkoff, Gabrielle R. Yankelevich, Daniel C. Edwards, Meghan Buckley, and Paulette C. Dreher

Subjects
Geospatial analysis, business.industry, Urology, Environmental health, Tobacco exposure, Socio environmental, Medicine, Institutional analysis, Urologic Neoplasms, business, computer.software_genre, computer, Urothelial carcinoma
Abstract

INTRODUCTION AND OBJECTIVE:Industrial byproducts and environmental pollutants (IBP/EP) are associated with development of urothelial carcinoma (UC). While tobacco exposure (TE) is the major risk fa...

Published
2021

50. Spermatic Cord Block Series as a Minimally Invasive Therapy for Chronic Scrotal Content Pain

Author

Kelsey M. Lynch, Petar Bajic, Daniel Simon, and Laurence A. Levine

Subjects
medicine.medical_specialty, business.industry, Local anesthetic, medicine.drug_class, Urology, medicine.medical_treatment, Chronic pain, medicine.disease, Spermatic cord, Surgery, medicine.anatomical_structure, Nerve block, Medicine, business
Abstract

Purpose:The primary aim of our study was to evaluate relief of chronic scrotal content pain after a series of spermatic cord blocks with a combination of local anesthetic and a steroid. Secondary a...

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results